CAS 1953-04-4|Galantamine hydrobromide
| Common Name | Galantamine hydrobromide | ||
|---|---|---|---|
| CAS Number | 1953-04-4 | Molecular Weight | 368.266 |
| Density | / | Boiling Point | / |
| Molecular Formula | C17H22BrNO3 | Melting Point | 256 °C |
| MSDS | ChineseUSA | Flash Point | / |
| Symbol | GHS06 | Signal Word | Danger |
Names
| Name | Galanthamine hydrobromide |
|---|---|
| Synonym | More Synonyms |
Galantamine hydrobromide BiologicalActivity
| Description | Galanthamine hydrobromide is a long-acting, centrally active acetylcholinesterase(AChE) inhibitor (IC50 = 410 nM) and allosteric potentiator at neuronal nicotinic ACh receptors. IC50 Value: 410 nM Target: AChEGalanthamine hydrobromide prevents β-amyloid-induced apoptosis in SH-SY5Y and bovine chromaffin cells. Long-term administration reduces amyloid precursor protein deposition and neurodegeneration in a mouse model of Alzheimer's disease. |
|---|---|
| Related Catalog | Signaling Pathways >>Neuronal Signaling >>AChEResearch Areas >>Neurological Disease |
| References | [1]. Kita Y, Ago Y, Takano E, Fukada A, Takuma K, Matsuda T.Galantamine increases hippocampal insulin-like growth factor 2 expression via α7 nicotinic acetylcholine receptors in mice.Psychopharmacology (Berl). 2012 Aug 30. [2]. Berkov S, Viladomat F, Codina C, Suárez S, Ravelo A, Bastida J.GC-MS of amaryllidaceous galanthamine-type alkaloids.J Mass Spectrom. 2012 Aug;47(8):1065-73. [3]. Park CW, Son DD, Kim JY, Oh TO, Ha JM, Rhee YS, Park ES.Investigation of formulation factors affecting in vitro and in vivo characteristics of a galantamine transdermal system.Int J Pharm. 2012 Oct 15;436(1-2):32-40. Epub 2012 Jul 5. [4]. Park YS, Kim SH, Kim SY, Kim YH, Lee MH, Yang SC, Shaw LM, Kang JS.Quantification of Galantamine in Human Plasma by Validated Liquid Chromatography-Tandem Mass Spectrometry using Glimepride as an Internal Standard: Application to Bioavailability Studies in 32 Healthy Korean Subjects.J Chromatogr Sci. 2012 Jun 28. [5]. Arias et al Galantamine prevents apoptosis induced by b-amyloid and thapsigargin: involvement of nicotinic acetycholine receptors. Neuropharmacology (2004) 46 103. |
Chemical & Physical Properties
| Melting Point | 256 °C |
|---|---|
| Molecular Formula | C17H22BrNO3 |
| Molecular Weight | 368.266 |
| Exact Mass | 367.078308 |
| PSA | 41.93000 |
| LogP | 2.74630 |
| Vapour Pressure | 0mmHg at 25°C |
| Index of Refraction | -95 ° (C=1.4, H2O) |
| InChIKey | QORVDGQLPPAFRS-XPSHAMGMSA-N |
| SMILES | Br.COc1ccc2c3c1OC1CC(O)C=CC31CCN(C)C2 |
| Storage condition | −20°C |
Safety Information
| Symbol | GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H301 |
| Precautionary Statements | P301 + P310 |
| Personal Protective Equipment | Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges |
| Hazard Codes | T |
| Risk Phrases | R25:Toxic if swallowed. |
| Safety Phrases | 45-36/37/39-22 |
| RIDADR | UN 2811 6.1/PG 3 |
| WGK Germany | 3 |
| RTECS | DF8075000 |
Articles40
More Articles| Systematic evaluation of commercially available ultra-high performance liquid chromatography columns for drug metabolite profiling: optimization of chromatographic peak capacity. J. Chromatogr. A. 1374 , 122-33, (2014) The present study investigated the practical use of modern ultra-high performance liquid chromatography (UHPLC) separation techniques for drug metabolite profiling, aiming to develop a widely applicab... | |
| Galantamine-loaded PLGA nanoparticles, from nano-emulsion templating, as novel advanced drug delivery systems to treat neurodegenerative diseases. Nanoscale 7 , 12076-84, (2015) Polymeric nanoparticles could be promising drug delivery systems to treat neurodegenerative diseases. Among the various methods of nanoparticle preparation, nano-emulsion templating was used in the pr... | |
| Acetylcholine excites neocortical pyramidal neurons via nicotinic receptors. J. Neurophysiol. 113 , 2195-209, (2015) The neuromodulator acetylcholine (ACh) shapes neocortical function during sensory perception, motor control, arousal, attention, learning, and memory. Here we investigate the mechanisms by which ACh a... |
Synonyms
| (4aS,6R,8aS)-3-Methoxy-11-methyl-5,6,9,10,11,12-hexahydro-4aH-[1]benzofuro[3a,3,2-ef][2]benzazepin-6-olhydrobromid |
| NIVALIN,HBR |
| MFCD00067672 |
| (4aS,6R,8aS)-3-methoxy-11-methyl-5,6,9,10,11,12-hexahydro-4aH-[1]benzofuro[3a,3,2-ef][2]benzazepin-6-ol hydrobromide |
| (4aS,6R,8aS)-3-méthoxy-11-méthyl-5,6,9,10,11,12-hexahydro-4aH-[1]benzofuro[3a,3,2-ef][2]benzazépin-6-ol bromhydrate |
| Galanthamine hydrobromide (1:1) |
| GALANTHAMIDE HYDROBROMIDE |
| [3H]-Galantamine hydrobromide |
| UNII:5N4SA4KQX9 |
| galanthamine bromhydrate (1:1) |
| Galantamine hydrobromide (JAN/USAN) |
| Galanthamine HBr |
| Galanthamine (hydrobromide) |
| Galantamine hydrobromide |
| (-)-Galanthaminium bromide |
| NIVALIN |
| 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aS,6R,8aS)-, hydrobromide (1:1) |
| galanthaminhydrobromid(1:1) |
| GALANTHAMINE HYDROBROMIDUM |
| EINECS 217-780-5 |
| GALANTAMINE HBR |
| 6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aS,6R,8aS)-, hydrobromide |
